Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee‐Shing Chang, Romualdo Barroso‐Sousa, Sara M. Tolaney, et al.
Endocrine Reviews (2018) Vol. 40, Iss. 1, pp. 17-65
Open Access | Times Cited: 439

Showing 1-25 of 439 citing articles:

Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1020
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
Immune Network (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 215
Hypothyroidism
Layal Chaker, Salman Razvi, Isabela M. Benseñor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 201
An update on the pathogenesis of Hashimoto’s thyroiditis
Anthony P. Weetman
Journal of Endocrinological Investigation (2020) Vol. 44, Iss. 5, pp. 883-890
Open Access | Times Cited: 177
Adrenal insufficiency
Stefanie Hahner, Richard Ross, Wiebke Arlt, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Closed Access | Times Cited: 110
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S. Husebye, Fréderic Castinetti, Sherwin Criseno, et al.
European Journal of Endocrinology (2022) Vol. 187, Iss. 6, pp. G1-G21
Open Access | Times Cited: 79
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 3, pp. e006398-e006398
Open Access | Times Cited: 76
Hyperglycemic Crises in Adults With Diabetes: A Consensus Report
Guillermo E. Umpierrez, Georgia M. Davis, Nuha A. ElSayed, et al.
Diabetes Care (2024) Vol. 47, Iss. 8, pp. 1257-1275
Open Access | Times Cited: 45
Hyperglycaemic crises in adults with diabetes: a consensus report
Guillermo E. Umpierrez, Georgia M. Davis, Nuha A. ElSayed, et al.
Diabetologia (2024) Vol. 67, Iss. 8, pp. 1455-1479
Open Access | Times Cited: 30
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update
Seth J. Rotz, Neel S. Bhatt, Betty K. Hamilton, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 4, pp. 349-385
Open Access | Times Cited: 24
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Anupam Kotwal, Lisa A. Kottschade, Mabel Ryder
Thyroid (2019) Vol. 30, Iss. 2, pp. 177-184
Open Access | Times Cited: 145
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 139
Drug Effects on the Thyroid
Henry B. Burch
New England Journal of Medicine (2019) Vol. 381, Iss. 8, pp. 749-761
Closed Access | Times Cited: 125
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
Neeraj Chhabra, Joseph M. Kennedy
Journal of Medical Toxicology (2021) Vol. 17, Iss. 4, pp. 411-424
Open Access | Times Cited: 100
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Maria Stelmachowska‐Banaś, Izabella Czajka-Oraniec
Endocrine Connections (2020) Vol. 9, Iss. 10, pp. R207-R228
Open Access | Times Cited: 99
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
Virginie Grouthier, Bénédicte Lebrun‐Vignes, Melissa Moey, et al.
The Oncologist (2020) Vol. 25, Iss. 8, pp. 696-701
Open Access | Times Cited: 97
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
Keywan Mortezaee, Masoud Najafi
Critical Reviews in Oncology/Hematology (2020) Vol. 157, pp. 103180-103180
Closed Access | Times Cited: 92
Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society
Hiroshi Arima, Shintaro Iwama, Hidefumi Inaba, et al.
Endocrine Journal (2019) Vol. 66, Iss. 7, pp. 581-586
Open Access | Times Cited: 87
MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
F. Albarel, Frédéric Castinetti, Thierry Brue
European Journal of Endocrinology (2019) Vol. 181, Iss. 3, pp. R107-R118
Open Access | Times Cited: 82
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency
Seiichi Yano, Kenji Ashida, Ryuichi Sakamoto, et al.
European Journal of Cancer (2020) Vol. 130, pp. 198-203
Closed Access | Times Cited: 76
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Shima Makaremi, Zahra Asadzadeh, Nima Hemmat, et al.
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1075-1075
Open Access | Times Cited: 67
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Remo Poto, Teresa Troiani, Gjada Criscuolo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 67
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
Yee-Ming Melody Cheung, Wei Wang, Bradley A. McGregor, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 8, pp. 1795-1812
Open Access | Times Cited: 56
Immune checkpoint inhibitor-related thyroid dysfunction
Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 36, Iss. 3, pp. 101660-101660
Open Access | Times Cited: 49
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Shlomit Jessel, Sarah A. Weiss, Matthew Austin, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 48
Page 1 - Next Page

Scroll to top